SCHEDULE: BlackRock Portfolio Management Discloses 6.2% Stake in REGENXBIO INC

BlackRock Portfolio Management LLC has disclosed a 6.2% beneficial ownership stake in REGENXBIO INC, totaling 3,133,608 common shares, as of June 30, 2025.

Summary

• BlackRock Portfolio Management LLC filed a Schedule 13G, reporting its beneficial ownership in REGENXBIO INC.
• The filing indicates beneficial ownership of 3,133,608 shares of REGENXBIO INC common stock.
• This ownership represents 6.2% of the total outstanding common stock of REGENXBIO INC.
• BlackRock Portfolio Management LLC holds sole voting power over 2,703,502 shares and sole dispositive power over 3,133,608 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of REGENXBIO INC.
• The filing was made by BlackRock Portfolio Management LLC as a parent holding company, with various BlackRock subsidiaries identified as entities that may beneficially own 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a major institutional investor like BlackRock is generally viewed positively as it indicates confidence and liquidity, without suggesting any immediate negative implications or activist intentions.

Positives

• A significant stake by a major institutional investor like BlackRock Portfolio Management LLC indicates confidence in REGENXBIO INC.
• The stated purpose of holding shares in the ordinary course of business suggests a passive, long-term investment, which can contribute to stock stability.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding REGENXBIO INC's future performance or BlackRock's investment strategy beyond the current ownership disclosure.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing reflects a significant passive investment by a major asset manager, BlackRock, in REGENXBIO INC. Such institutional ownership is common across various industries, including biotechnology, and often signals a long-term investment perspective rather than an active or activist stance, consistent with the nature of a Schedule 13G filing.

Comparison to Industry Standards

• A 6.2% stake by a major institutional investor like BlackRock is a notable position, though not uncommon for large asset managers holding diversified portfolios.
• While specific comparable companies or projects are not detailed in this filing, such an ownership percentage is generally considered a significant, but passive, investment within the context of institutional portfolio management, aligning with typical investment strategies for diversified funds.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be perceived positively, potentially enhancing stock stability and liquidity.
• Management: No direct impact on management control or strategy is indicated, as the filing states the shares are not held for influencing control.

Next Steps

• BlackRock Portfolio Management LLC will continue to monitor its investment in REGENXBIO INC.
• Further Schedule 13G/A filings would be required if beneficial ownership changes significantly (e.g., crosses 10% or drops below 5%).

Key Dates

Keywords

REGENXBIO INC, BlackRock Portfolio Management LLC, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing